Zimmer Biomet Declares $0.24 Dividend, Payable June 25
0h ago|4 min readStandard
Fazen Markets Editorial Desk
Collective editorial team · methodology
dividendzimmer-biomet
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD 24/5 on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. Vortex HFT is informational software — not investment advice. Past performance does not guarantee future results.
Zimmer Biomet Holdings announced on 23 May 2026 that its board declared a quarterly cash dividend of $0.24 per share on outstanding common stock. The dividend is payable on 25 June 2026 to shareholders of record as of 14 June 2026. The declaration continues the company’s long-standing quarterly cash dividend program, which it has maintained through several business cycles and strategic shifts. The current annualized payout of $0.96 per share represents a forward yield of approximately 0.98% based on the stock's recent trading price around $98.
The dividend declaration arrives as Zimmer Biomet accelerates its strategic focus on high-growth segments like robotics and digital surgery. The company has consistently paid dividends since its spin-off from Bristol-Myers Squibb in 2001, a track record spanning over two decades. This stability is notable within the capital-intensive orthopedics sector, where companies like Stryker and Medtronic also maintain dividend programs while funding significant research and acquisition activity.
Current market conditions highlight the importance of reliable income streams. The Federal Reserve’s policy rate remains elevated at 4.75%, making yield-generating equities more attractive relative to lower-risk fixed income for some investors. Zimmer's commitment to the dividend signals confidence in its cash flow generation despite ongoing investments in new product cycles.
The timing is also significant relative to recent performance. The company reported first-quarter 2026 adjusted earnings per share of $2.15, surpassing analyst estimates. This earnings beat and strong revenue guidance provided the underlying financial strength that supports the consistent dividend return to shareholders in the current quarter.
The declared $0.24 quarterly dividend aligns with the company's previous payout, maintaining a streak of 96 consecutive quarterly dividends. Based on trailing twelve-month adjusted earnings per share of $8.40, the dividend payout ratio is approximately 28%, a conservative level that leaves ample room for reinvestment and debt reduction. The company ended Q1 2026 with about $400 million in cash and equivalents and a net debt position of $5.8 billion.
Comparing the yield to peers illustrates competitive positioning. Zimmer’s forward yield of 0.98% compares to Stryker’s 0.91% and Medtronic’s 3.2%. The lower yield relative to Medtronic reflects differing capital allocation strategies and growth expectations. Zimmer’s dividend has grown at a compound annual rate of roughly 2.5% over the past five years.
| Metric | Zimmer Biomet | S&P 500 Index |
|---|---|---|
| Forward Dividend Yield | 0.98% | 1.42% |
| 5-Year Dividend Growth (CAGR) | ~2.5% | ~5.8% |
Share repurchases provide another capital return avenue. The company had $1.2 billion remaining under its current share repurchase authorization as of the latest earnings report, representing about 4% of its $30 billion market capitalization.
The dividend reaffirmation is a positive signal for the broader medical device sector, suggesting foundational cash flow stability even amid pricing pressure and procedure volume normalization. It benefits income-focused healthcare ETFs like the Health Care Select Sector SPDR Fund (XLV) and the iShares U.S. Medical Devices ETF (IHI), which hold significant positions in Zimmer. The steady payout may also attract generalist dividend investors who previously overlooked the stock due to its moderate yield.
A key risk is that the dividend’s low growth rate may lag inflation, potentially making the stock less attractive to income investors seeking real yield growth. the company’s substantial debt load requires consistent free cash flow, which could be pressured by a significant slowdown in elective orthopedic procedures.
Positioning data indicates that institutional ownership remains high, around 90%. The dividend declaration is unlikely to trigger major new inflows but reinforces the stock’s defensive characteristics in volatile markets. Options flow preceding the announcement showed modest buying of short-dated calls, suggesting some traders anticipated a positive catalyst.
The next major catalyst for Zimmer Biomet is its second-quarter 2026 earnings report, scheduled for late July. Analysts will scrutinize sales growth in key segments like knees, hips, and the Rosa robotics platform for confirmation of sustained cash flow. Any deviation from the expected $1.95 billion in Q2 revenue could influence future capital return decisions.
Investors should monitor the 50-day moving average, currently near $96.50, as a key technical support level. A sustained break above the $100 psychological resistance would require a combination of strong earnings and upward revisions to full-year guidance.
Regulatory developments pose another watch item. The FDA’s review cycle for new orthopedic implants and robotic surgical systems can impact long-term revenue streams. A favorable decision on a pending application for a new knee system could enhance long-term cash flow security and support future dividend increases.
Zimmer Biomet's forward dividend yield is approximately 0.98%, calculated by annualizing the $0.24 quarterly payout against a share price near $98. This yield sits below the current average for the S&P 500, which is around 1.42%, but is typical for growth-oriented medtech firms that prioritize reinvesting profits into research and acquisitions alongside shareholder returns.
Zimmer Biomet pays dividends on a quarterly schedule. The company has an unbroken record of quarterly payments for over 24 years, a hallmark of financial discipline in the cyclical healthcare sector. The upcoming payment on 25 June 2026 follows this established cadence, with subsequent payouts typically expected in September, December, and March.
Yes, Zimmer Biomet offers a Dividend Reinvestment Plan (DRIP) that allows shareholders to automatically reinvest their cash dividends into additional shares of common stock, often without paying brokerage commissions. The plan details, including any fees or discounts, are administered by the company’s transfer agent and provide a cost-effective method for long-term investors to compound their holdings.
Zimmer Biomet's steady dividend underscores its mature profitability and cash flow resilience in a transitioning orthopedics market.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
Vortex HFT is our free MT4/MT5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. Trades 24/5.
Position yourself for the macro moves discussed above
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.